Create Free Account

By creating account you will get access to hot stocks & personalised emails

Rhinomed Ltd

Healthcare AU RNO

NoneAUD
-(-%)

Last update at 2024-03-12T06:45:07.441872Z

Day Range

--
LowHigh

52 Week Range

0.020.10
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -11.05531M -5.28020M -8.63781M -7.26543M -6.05412M
Minority interest - - - - -
Net income -11.05609M -5.28104M -8.63893M -7.26622M -6.06617M
Selling general administrative 6.41M 5.10M 6.91M 6.02M 4.66M
Selling and marketing expenses 5.62M 4.76M 3.36M 2.59M 2.22M
Gross profit 5.59M 6.21M 2.75M 2.12M 2.19M
Reconciled depreciation 0.89M 0.70M 0.59M 0.60M 0.40M
Ebit -8.25594M -5.23595M -8.59697M -8.08518M -6.13886M
Ebitda -7.36396M -4.53649M -8.00541M -7.48921M -5.74334M
Depreciation and amortization 0.89M 0.70M 0.59M 0.60M 0.40M
Non operating income net other - - - - -
Operating income -9.41019M -6.02559M -8.85044M -7.23470M -6.13886M
Other operating expenses 18.94M 14.86M 13.05M 11.61M 9.42M
Interest expense 0.31M 0.04M 0.04M 0.04M 0.08M
Tax provision 0.00078M 0.00084M 0.00111M 0.00079M 0.01M
Interest income 0.31M 0.00221M 0.03M 0.01M 0.02M
Net interest income -0.31027M -0.04204M -0.01138M 0.01M 0.02M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00078M 0.00084M 0.00111M 0.00079M 0.01M
Total revenue 7.47M 9.10M 3.89M 3.57M 3.29M
Total operating expenses 14.89M 12.73M 12.13M 10.20M 8.33M
Cost of revenue 1.88M 2.90M 1.14M 1.45M 1.09M
Total other income expense net -1.44255M 1.29M 0.75M 0.81M 0.08M
Discontinued operations - - - - -
Net income from continuing ops -11.05609M -5.28104M -8.63893M -7.26622M -5.94074M
Net income applicable to common shares -11.05609M -5.28104M -8.63893M -7.26622M -5.94074M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 3.14M 8.50M 6.55M 12.81M 5.87M
Intangible assets 0.31M 0.31M 0.67M 1.03M 1.39M
Earning assets - - - - -
Other current assets 0.21M 0.20M 0.12M 0.25M 0.42M
Total liab 9.69M 3.46M 1.78M 1.96M 1.25M
Total stockholder equity -6.55359M 5.03M 4.76M 10.86M 4.62M
Deferred long term liab - 0.07M 0.12M 0.16M 0.19M
Other current liab 0.94M 0.25M -0.43901M 0.12M 0.56M
Common stock 77.65M 77.65M 71.27M 71.27M 59.24M
Capital stock 77.65M 77.65M 71.27M 71.27M 59.24M
Retained earnings -86.54039M -75.48430M -71.12711M -62.79963M -56.29183M
Other liab 0.08M 0.08M 0.06M 0.08M 0.05M
Good will 1.57M 1.57M 1.57M 1.57M 1.57M
Other assets - 0.08M 0.12M 0.16M 0.19M
Cash 0.19M 1.99M 2.34M 7.76M 1.42M
Cash and equivalents - - - - -
Total current liabilities 9.59M 3.20M 1.38M 1.41M 1.20M
Current deferred revenue 0.13M 0.13M 0.61M 0.61M 0.56M
Net debt 5.79M -1.65240M -1.86915M -7.16932M -0.83317M
Short term debt 5.96M 0.15M 0.13M 0.12M -0.65882M
Short long term debt 5.79M - - - -
Short long term debt total 5.98M 0.34M 0.47M 0.59M 0.59M
Other stockholder equity -1.24057M -2.16648M -0.14191M -8.77162M 0.01M
Property plant equipment 0.46M 1.02M 0.48M 0.65M 0.22M
Total current assets 2.59M 5.52M 3.75M 9.49M 2.61M
Long term investments - 0.08M 0.08M 0.08M 0.09M
Net tangible assets -6.40576M 3.16M 2.65M 8.43M 1.86M
Short term investments 0.00054M 0.05M 0.02M 0.01M -
Net receivables 1.56M 2.09M 1.13M 0.94M 0.57M
Long term debt - - - - -
Inventory 0.63M 1.24M 0.16M 0.54M 0.34M
Accounts payable 2.56M 2.67M 1.07M 0.56M 0.75M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 2.34M 2.87M 4.62M 2.38M 1.65M
Additional paid in capital - - - - -
Common stock total equity - - - 71.27M 59.24M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.08M 0.08M -2.68124M -3.16291M 3.26M
Deferred long term asset charges - - - - -
Non current assets total 0.54M 2.97M 2.80M 3.32M 3.26M
Capital lease obligations 0.19M 0.34M 0.47M 0.59M -
Long term debt total 0.01M 0.19M 0.34M 0.47M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.09525M -0.87675M -0.04908M 0.00632M -0.03500M
Change to liabilities -0.11067M 1.60M 0.52M -0.05627M -0.10130M
Total cashflows from investing activities -0.09525M -0.87675M -0.04908M -0.00471M -0.26580M
Net borrowings 5.46M -0.16502M -0.16502M -0.16502M -0.16502M
Total cash from financing activities 5.46M 6.22M -0.02240M 12.05M 4.86M
Change to operating activities 0.48M 0.09M -0.13395M 0.12M -0.18760M
Net income -10.90826M -5.28104M -8.63893M -7.26622M -6.06617M
Change in cash -1.79454M -0.35048M -5.41786M 6.34M 0.16M
Begin period cash flow 1.98M 2.34M 7.76M 1.42M 1.26M
End period cash flow 0.19M 1.99M 2.34M 7.76M 1.42M
Total cash from operating activities -7.17795M -5.74348M -5.21731M -5.74026M -4.70994M
Issuance of capital stock - 6.65M - 12.51M 5.09M
Depreciation 0.85M 0.70M 0.59M 0.60M 0.40M
Other cashflows from investing activities - - 0.00000M 0.00632M -0.03500M
Dividends paid -0.43602M 0.33M - - -
Change to inventory -0.28179M -1.08459M 0.38M -0.20341M 0.02M
Change to account receivables 0.60M -0.96033M -0.18846M -0.30473M 0.44M
Sale purchase of stock -0.26325M -0.26325M -0.02240M -0.46476M -0.23219M
Other cashflows from financing activities -0.15130M -0.16502M -12.51444M -0.00471M -0.03500M
Change to netincome 2.16M -1.12642M 2.14M 1.38M 0.88M
Capital expenditures 0.10M 0.88M 0.05M 0.01M 0.23M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.31M -2.04492M 0.19M -0.50814M 0.08M
Stock based compensation - - 2.10M 1.47M -
Other non cash items 2.57M 0.88M 2.83M 0.93M 5.55M
Free cash flow -7.27320M -6.62023M -5.26639M -5.75128M -4.94073M

Fundamentals

  • Previous Close 0.04
  • Market Cap11.47M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-8.69138M
  • Revenue TTM8.05M
  • Revenue Per Share TTM0.03
  • Gross Profit TTM 5.28M
  • Diluted EPS TTM-0.04

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RNO
Rhinomed Ltd		 - -% - - - 1.42 119.98 2.31 -1.7749
COH
Cochlear Ltd		 -0.88 0.28% 316.29 59.34 46.30 9.75 11.76 9.62 36.63
PNV
Polynovo Ltd		 -0.04 1.95% 2.01 - 140.85 17.37 21.49 17.51 647.42
AVR
Anteris Technologies Ltd		 -0.4 1.84% 21.30 - - 104.23 14.98 95.15 -5.9152
AVH
Avita Therapeutics Inc		 0.10 3.80% 2.73 - - 8.59 5.71 6.72 -10.0538

Reports Covered

Stock Research & News

View All

Profile

Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. The company offers wearable nasal technology that improve breathing, sleeping, and maintaining health and diagnose disease. Its products include Turbine for enhanced breathing in sports; Mute, which helps to breath more and snore less; Pronto, a vapor inhaler to improve airflow and better sleep; and Rhinoswab that is used to collect a nasal swab. The company also engages in developing programs in various markets, including sleep and sleep architecture, the impact of sleep and respiratory, function on cognitive issues, obstructive sleep apnea, pain, nausea, respiratory disease, and diagnostics and sensors; and offers a drug delivery platform for the delivery of cannabinoid formulations. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is based in Cremorne, Australia.

Rhinomed Ltd

132 Gwynne Street, Cremorne, VIC, Australia, 3121

Key Executives

Name Title Year Born
Mr. Michael Johnson CEO, MD & Exec. Director NA
Mr. Sean Slattery CFO & Company Sec. NA
Mr. Michael Johnson CEO, MD & Executive Director NA
Mr. Sean Slattery CFO & Company Secretary NA
Mr. Michael Johnson CEO, MD & Executive Director NA
Mr. Sean Slattery CFO & Company Secretary NA
Mr. Michael Johnson CEO, MD & Executive Director NA
Mr. Sean Slattery CFO & Company Secretary NA
Mr. Michael Johnson CEO, MD & Executive Director NA
Mr. Sean Slattery CFO & Company Secretary NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Our Company

Useful Links

Contact Us

Market Research

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.